Ocrelizumab - Biogen/Genentech
At a glance
- Drug Originator Biogen Idec; Genentech
- Drug Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Urologics
- Mechanism of Action Antibody-dependent cell cytotoxicity
- USA Patent Applicants GENENTECH INC
- USA Patents 85
- BLAs 1
- International Patents 1,168
Disclaimer